semaglutide 2 Use of linked to doubled risk of neovascular macular degeneration Semaglutide Information – Neuday

Wegovy (semaglutide) is a GLP-1 receptor agonist licensed for weight management that commonly causes gastrointestinal side effects including nausea, diarrhoea, and constipation

Apply moderate amount with dry hands and spread all over face like massaging

Why Klinic Prioritizes Weight Loss-Specific Medications Over Ozempic Ozempic serves a different role, focusing on type 2 diabetes management

What to Expect in the First Few Weeks of Treatment The first two to four weeks are typically characterised by gastrointestinal side effects and modest appetite suppression, with significant weight loss usually becoming evident from weeks four to eight as the dose increases